Thus, mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 define specific entities, associated with lower histologic grades and better prognosis when compared to IDH-wild-type astrocytomas [3]. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).